Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C](+)-3-MPB (also known as (+)N-[11C]methyl-3-piperidyl benzilate) is a carbon-11 labeled radiopharmaceutical developed as a positron emission tomography (PET) imaging agent. It acts as a non-selective antagonist of muscarinic acetylcholine receptors (mAChRs) in the brain. Developed by researchers at the Research Institute for Brain and Blood Vessels Akita and Hamamatsu Photonics, [11C](+)-3-MPB is used in preclinical and clinical research to evaluate central muscarinic receptor density, occupancy by therapeutic agents (such as scopolamine, oxybutynin, and solifenacin), and alterations in cholinergic system function associated with aging, chronic fatigue syndrome (CFS), and other neurological or psychiatric disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C](+)-3-MPB.